About Us

About Us

Forward
Pharma

A Research-Driven Biotechnology Company

Forward Pharma is a clinical-stage biotechnology company driven by research and discovery. Our core research facilities and discovery teams are based in Shenzhen, with clinical development headquartered in Shanghai. We focus exclusively on oncology, with the goal of developing next-generation best-in-class and first-in-class therapies. Currently, we have two de novo discovered programs advanced to clinical stage.


Image

History

2015

2015/10 - Forward Pharma founded.


2017

2017/02 - Closed seed round financing.

2017/04 - Established internal R&D team in Nanshan Hi-Tech Park, Shenzhen.

2018

2018/07 - Established the "Anti-tumor Innovative Drug R&D Center" in collaboration with the Research Institute of Tsinghua University in Shenzhen (RITS).

2019

2019/04 - Closed Pre-A round financing lead by League.

2019/06 - Established strategic global partnership with WuXi AppTec, a global leader in contract research organizations (CROs).


2021

2021/05 - Completed Series A financing lead by CSPC & Sangel Capital.

2021/11 - IND-enabling initiated for FWD1802 targeting ER+/HER2- breast cancer.

2022

2022/01 - Clinical development headquarter in operation in Shanghai.

2023

2023/05 - Completed Series A+ financing lead by V-Fund.

2023/07 - IND approvals for FWD1802 in the U.S. and China.

2024

2024/12 - FWD1802 completed dose escalation/expansion Phase I study and initiated Phase II trials.

2024/12 - Forward Wuhan in operation.


2025

2025/04 - Closed Series B financing lead by Wuhan Hi-Tech Holding Group Co., Ltd.

2025/06 - NMPA IND cleared for FWD1802 comination therapy.


2015

2017

2018

2019

2021

2022

2023

2024

2025

 

联系我们

提交您的信息,我们将尽快与您联系
×